Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
URG501
- Development stage
- Preclinical
- Lead developer
- Urigen Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
URG501 is a pentosan-based glycosaminoglycan (GAG) replacement therapy being developed by Urigen Pharmaceuticals for the treatment of Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). The drug is designed to restore or support the protective GAG layer of the bladder epithelium, which is often deficient or damaged in patients suffering from IC/BPS. By replenishing this layer, URG501 aims to prevent irritating urinary components from penetrating the bladder wall and causing inflammation and pain. URG501 is a small molecule formulation based on pentosan polysulfate sodium, which is currently the only FDA-approved oral therapy for this indication.
- Other names
- pentosan polysulfate sodium
Beyond the preview
Go deeper on URG501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on URG501.